[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369315-105":59,"doc-detail-369315-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","spillover-effects-of-medicare-advantage-on-traditional-medicare-beneficiaries-with-prostate-cancer-research-article","Spillover Effects of Medicare Advantage on Traditional Medicare Beneficiaries With Prostate Cancer - Research Article","","Medicare Advantage managed care plans, selected by many Medicare beneficiaries, use financial incentives to constrain healthcare spending and utilization, potentially affecting care beyond their enrolled populations. Using Medicare claims for patients diagnosed with prostate cancer (2016–2019), practice-level MA penetration was calculated and analyzed against quality and utilization outcomes. Higher MA penetration increased the odds of overall treatment among Traditional Medicare beneficiaries but showed no association with potential overtreatment, confirmatory testing, or price-standardized spending.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/spillover-effects-of-medicare-advantage-on-traditional-medicare-beneficiaries-with-prostate-cancer-research-article/369315/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/spillover-effects-of-medicare-advantage-on-traditional-medicare-beneficiaries-with-prostate-cancer-research-article/369315.png","ImageObject",300,407,{"name":92,"@type":93},"River Wang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What spillover effect did the study examine?","Question",{"text":113,"@type":114},"The study examined whether Medicare Advantage incentives affect physician behavior and, consequently, outcomes for Traditional Medicare beneficiaries with prostate cancer through spillover effects.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was MA penetration measured in the study?",{"text":118,"@type":114},"MA penetration was measured at the practice level as the proportion of MA beneficiaries relative to Traditional Medicare and MA beneficiaries.",{"name":120,"@type":111,"acceptedAnswer":121},"What relationship did the study find between MA penetration and treatment and quality?",{"text":122,"@type":114},"Higher practice-level MA penetration was associated with higher odds of overall treatment among all Traditional Medicare beneficiaries, but it was not associated with the quality measures (potential overtreatment and confirmatory testing) or price-standardized spending.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},369315,1790791579,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":46,"preview_page_count":19,"preview_urls":145},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","Cancer Medicine  \nRESEARCH ARTICLE  OPEN ACCESS   \nSpillover Effects of Medicare Advantage on Traditional Medicare Beneficiaries With Prostate Cancer  \nArnav Srivastava1  | Samuel R. Kaufman1 | Xiu Liu2 | Avinash Maganty2 | Addison Shay1  | Mary Oerline1 | Christopher Dall2 | Kassem S. Faraj1  | Paula Guro1  | Dawson Hill1 | Thuy Nguyen3 |  \nLindsey A. Herrel1  | Brent K. Hollenbeck1 | Vahakn B. Shahinian1  \n1Dow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, Michigan, USA | 2Department of Urology, Massachusetts General Hospital, Boston, Massachusetts, USA | 3Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor, Michigan, USA  \nCorrespondence: Arnav Srivastava ([srivasar@med.umich.edu](srivasar@med.umich.edu); [arnavsrivastava.md.mph@gmail.com](arnavsrivastava.md.mph@gmail.com))  \nReceived: 21 December 2024 | Revised: 7 March 2025 | Accepted: 11 March 2025  \nFunding: This work was supported by National Cancer Institute, R01 CA269367, R01 CA279746, T32 CA180984 .  \nKeywords: active surveillance | financial incentives | Medicare | medicare advantage | prostate cancer  \nABSTRACT  \nIntroduction: Medicare Advantage (MA) managed care plans, now chosen by 51% of Medicare beneficiaries, are incentivized to constrain healthcare spending and utilization, a shift in financial incentives compared to Traditional Medicare's fee-for-service payment model. Beyond its primary beneficiaries, MA's mechanisms to constrain utilization may impact Traditional Medicare beneficiaries with prostate cancer through “spillover” effects on physician behavior.  \nMethods: From a 20% sample of Medicare claims, we identified patients diagnosed with prostate cancer from 2016 to 2019. We calculated MA penetration [MA beneficiaries/(Traditional Medicare and MA beneficiaries)] at the practice-level. We assessed the relationship between practice-level MA penetration and two measures of quality—potential overtreatment (i.e., treatment among those with > 75% noncancer mortality within 10 years of diagnosis) and confirmatory testing (repeat prostate biopsy, MRI, or genomic test)—using a multilevel logistic regression. We also assessed two measures of utilization, price standardized spending (i.e., global utilization) and overall treatment.  \nResults: We identified 41,092 patients. Median practice-level MA penetration was 33%(IQR 23%–43%). Increasing practice-level MA penetration was associated with increased odds of overall treatment among all Traditional Medicare beneficiaries (adjusted OR 1.03 (95% CI 1.01–1.05), p = 0.01, per 10% increase in MA penetration). However, MA penetration was not associated with our quality measures, potential overtreatment and confirmatory testing, or price-standardized spending.  \nConclusions: MA penetration at the urology practice-level varies considerably. In men with prostate cancer, greater practicelevel MA penetration was associated with increased odds of treatment, but not overall utilization—even where it might influence quality.  \n1 | Background  \nPhysician discretion often contributes substantially to the variation in the use and implementation of conservative management in prostate cancer [1, 2] . Nearly 40% of men with  \nlow-risk disease undergo immediate treatment, despite being unlikely to benefit [3] . Even in men initiating active surveillance, which forgoes immediate treatment in favor of periodic reassessment of cancer risk, most do not receive all guidelinerecommended testing [4–7] . Importantly, up to 60% of men miss  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2025 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.  \nCancer Medicine, 2025; 14:e70796 1 of 8  \n[https://doi.org/10.1002/cam4.70796](https://doi.org/10.1002/cam4.70796)  \nguideline-rec","cbCaitnSNu3WP3g1","https://ap.wps.com/l/cbCaitnSNu3WP3g1","pdf",544059,"English","# Abstract\n## Introduction\n## Methods\n## Results\n## Conclusions\n# Background\n## Physician discretion and treatment variation\n## Active surveillance testing gaps\n## Incentives in Medicare and spillover hypothesis","[{\"question\":\"What spillover effect did the study examine?\",\"answer\":\"The study examined whether Medicare Advantage incentives affect physician behavior and, consequently, outcomes for Traditional Medicare beneficiaries with prostate cancer through spillover effects.\"},{\"question\":\"How was MA penetration measured in the study?\",\"answer\":\"MA penetration was measured at the practice level as the proportion of MA beneficiaries relative to Traditional Medicare and MA beneficiaries.\"},{\"question\":\"What relationship did the study find between MA penetration and treatment and quality?\",\"answer\":\"Higher practice-level MA penetration was associated with higher odds of overall treatment among all Traditional Medicare beneficiaries, but it was not associated with the quality measures (potential overtreatment and confirmatory testing) or price-standardized spending.\"}]","Spillover Effects of Medicare Advantage on Traditional Medicare Beneficiaries With Prostate Cancer - Research Article | PDF",1790181910,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/43f730242a232f1e42a811de349e3b1b.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/91858a86980acac71f9fdd510ab3efa4.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1ed0d7ff06db6cbad8a5356ed27b6a1e.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/28c0a2bd522e756ccfaea185112af205.webp",980,1287]